News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
FALBERG KATHRYN E
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/16/2023 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Gifted 50,504 shares
@ $0 Granted 6,800 shares
@ $0 Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
05/30/2023 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Granted 4,238 shares
@ $0 Granted 799 shares
@ $62.52, valued at
$50k
|
|
05/17/2023 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Nuvation Bio Inc.
Txns:
| Granted 366,744 options to buy
@ $1.64, valued at
$601.5k
|
|
02/09/2023 |
4/A
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc. |
02/08/2023 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Disposed/sold 21 shares
@ $59.83, valued at
$1.3k
|
|
12/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/28/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
06/16/2022 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Tricida, Inc.
Txns:
| Granted 27,207 options to buy
@ $9.87, valued at
$268.5k
|
|
06/16/2022 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 4,100 shares
@ $0 Granted 16,800 options to buy
@ $20.62, valued at
$346.4k
|
|
05/31/2022 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Granted 4,178 shares
@ $0 Granted 835 shares
@ $59.83, valued at
$50k
Granted 267 shares
@ $59.83, valued at
$16k
Granted 83 shares
@ $59.83, valued at
$5k
|
|
05/18/2022 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Nuvation Bio Inc.
Txns:
| Granted 118,784 options to buy
@ $4.05, valued at
$481.1k
|
|
11/23/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Sold 80,563 shares
@ $108.03, valued at
$8.7M
Sold 47,719 shares
@ $108.9, valued at
$5.2M
Sold 21,468 shares
@ $109.98, valued at
$2.4M
Sold 250 shares
@ $110.44, valued at
$27.6k
|
|
11/02/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Nuvation Bio Inc.
Txns:
| Granted 45,229 options to buy
@ $9.17, valued at
$414.7k
|
|
06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/09/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Granted 10,000 options to buy
@ $17.98, valued at
$179.8k
|
|
06/07/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 3,000 shares
@ $0 Granted 14,100 options to buy
@ $24.79, valued at
$349.5k
|
|
06/01/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Granted 390 shares
@ $0 Granted 78 shares
@ $639.65, valued at
$49.9k
Granted 25 shares
@ $639.65, valued at
$16k
Granted 7 shares
@ $639.65, valued at
$4.5k
|
|
04/02/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Bought 20,000 shares
@ $28.3498, valued at
$567k
|
|
02/12/2021 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Nuvation Bio Inc.
Txns:
| Granted 239,361 options to buy
@ $4.6, valued at
$1.1M
|
|
02/12/2021 |
3
| FALBERG KATHRYN E (Director) has filed a Form 3 on Nuvation Bio Inc. |
11/23/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Converted 20,000 shares
@ $0 Sold 232 shares
@ $806.63, valued at
$187.1k
Sold 795 shares
@ $807.84, valued at
$642.2k
Sold 1,853 shares
@ $809.03, valued at
$1.5M
Sold 2,852 shares
@ $810.19, valued at
$2.3M
Sold 5,670 shares
@ $811, valued at
$4.6M
Sold 200 shares
@ $811.68, valued at
$162.3k
Sold 891 shares
@ $813.04, valued at
$724.4k
Sold 10 shares
@ $814, valued at
$8.1k
Sold 1,891 shares
@ $815, valued at
$1.5M
Sold 4,139 shares
@ $818.15, valued at
$3.4M
|
|
10/14/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/15/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Tricida, Inc.
Txns:
| Granted 5,670 shares
@ $0 Granted 22,967 options to buy
@ $25.4, valued at
$583.4k
|
|
06/10/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Granted 10,000 options to buy
@ $28.24, valued at
$282.4k
|
|
06/08/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 3,000 shares
@ $0 Granted 14,000 options to buy
@ $30.05, valued at
$420.7k
|
|
05/29/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.
Txns:
| Granted 7,840 shares
@ $0 Granted 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
05/28/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Trade Desk, Inc.
Txns:
| Granted 901 shares
@ $0 Granted 180 shares
@ $249.66, valued at
$44.9k
Granted 64 shares
@ $249.66, valued at
$16k
Granted 20 shares
@ $249.66, valued at
$5k
|
|
11/13/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/14/2019 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Bought 12,935 shares
@ $8.5158, valued at
$110.2k
|
|
06/13/2019 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Bought 10,000 shares
@ $7.9, valued at
$79k
Bought 10,000 shares
@ $8.4928, valued at
$84.9k
|
|
06/11/2019 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Bought 22,065 shares
@ $7.9899, valued at
$176.3k
Bought 10,000 shares
@ $8.25, valued at
$82.5k
|
|
06/10/2019 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 35,000 options to buy
@ $7.99, valued at
$279.7k
|
|
06/05/2019 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Granted 10,000 options to buy
@ $34.83, valued at
$348.3k
|
|
06/04/2019 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Tricida, Inc.
Txns:
| Granted 1,879 shares
@ $0 Granted 7,068 options to buy
@ $36.74, valued at
$259.7k
|
|
|
|
|